Article Per Year (5 Year)
p-Index From 2021 - 2026
0.408
P-Index
This Author published in this journals
All Journal JURNAL PENELITIAN KEBIDANAN & KESPRO Journal of Innovative and Creativity
Nur Khalisha Yahya
Universitas Pertahanan Republik Indonesia
Education Health Professions Languange, Linguistic, Communication & Media Mathematics Social Sciences Other

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Therapeutic Options For Xanthelasma Palpebrarum: Pharmacological Approaches, Surgical Procedures, And Laser Therapy Joseph Bagasjati Pradika; ⁠Kamal Yasin; Bertrand Revival Hutagalung; Nur Khalisha Yahya; Amin Ibrizatun
Journal of Innovative and Creativity Vol. 6 No. 1 (2026)
Publisher : Fakultas Ilmu Pendidikan Universitas Pahlawan Tuanku Tambusai

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Xanthelasma palpebrarum is a benign skin lesion consisting of a yellowish periorbital plaque due to lipid accumulation, often associated with hyperlipidemia, although primarily an aesthetic complaint. This study aimed to evaluate the effectiveness, complications, and recurrence factors of three main modalities: surgical excision, CO2 laser, and LASIK.₂, and TCA. Using a qualitative systematic literature review approach based on PRISMA, the population included publications from 2021-2025 in Google Scholar, PubMed, and Scopus. The purposive sample consisted of 16 articles (500+ patients) with inclusion criteria of interventional studies and lipid profiles. The PRISMA protocol instrument and thematic content analysis identified patterns of effectiveness through triangulation and MMAT quality appraisal. The results showed that CO laser₂most effective (100% resolution, 13-16% recurrence), followed by surgical excision (3-60%), and TCA 70% for small lesions (25-39% recurrence) with a 33% risk of pigmentation. Conclusions recommend individualization of therapy based on lesion size, skin type, and systemic lipid management to minimize recurrence.
Efficacy and Safety of Labetalol Versus Methyldopa for Blood Pressure Control in Pregnant Women With Hypertension: Efficacy and Safety of Labetalol Versus Methyldopa for Blood Pressure Control in Pregnant Women With Hypertension Nur Khalisha Yahya
JURNAL ILMIAH DHDT - KEBIDANAN Vol 8 No 2 (2026): JURNAL PENELITIAN KEBIDANAN & KESPRO
Publisher : Fakultas Kebidanan Institut Kesehatan Deli Husada

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36656/jpk2r.v8i2.2891

Abstract

Hypertension in pregnancy is a major contributor to maternal morbidity and mortality worldwide. Labetalol and methyldopa are widely recommended as first-line antihypertensive therapy; however, uncertainty remains regarding comparative effectiveness for optimal blood pressure (BP) control. This Evidence-based case Report evaluates the efficacy and safety of these agents to inform therapeutic selection. A comprehensive literature search was conducted in PubMed, Cochrane Library, Google Scholar, and EBSCO using the keywords (“Hypertension” AND “Pregnancy” AND “Labetalol” AND “Methyldopa” AND “Blood Pressure Control”). Eligible studies included randomized controlled trials (RCTs) and systematic reviews/meta-analyses comparing labetalol and methyldopa in pregnant women with hypertension were included. Data extraction prioritized maternal BP outcomes, reporting effect sizes as relative risk (RR), absolute risk reduction (ARR), and number needed to treat (NNT) with 95% confidence intervals (CI). Quality assessment was performed using the Centre for Evidence-Based Medicine (CEBM) appraisal tool. From 355 studies screened, two RCTs met eligibility. Labetalol provided a faster reduction in blood pressure (RR 1.35; 95% CI 1.01–1.80; NNT ≈ 6), while overall blood pressure control was comparable to methyldopa in longer-term outcomes (RR 0.99; 95% CI 0.92–1.06).Both labetalol and methyldopa demonstrate comparable clinical effectiveness as first-line therapy for hypertension in pregnancy. Drug selection should be individualized based on clinical urgency, tolerance, availability, and monitoring capacity. Early treatment and close follow-up remain the primary determinants of maternal–fetal outcomes
Co-Authors Amin Ibrizatun Bertrand Revival Hutagalung Joseph Bagasjati Pradika ⁠Kamal Yasin